NCT07449728 The Influence of Laser Crossectomy With Different Wavelengths on Varicose Vein Progression
| NCT ID | NCT07449728 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pirogov Russian National Research Medical University |
| Condition | Varicose Veins |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-01-20 |
| Primary Completion | 2028-01-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2026-01-20 with a primary completion date of 2028-01-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Technically successful laser crossectomy will reduce the risk of reflux recurrence at the sapheno-femoral junction without increasing the risk of endovenous heat-induced thrombosis, which may positively impact the likelihood of ultrasound- or clinical-recurrence of varicose veins. Similar technical efficacy is expected for laser crossectomy at 1940 nm and 1470 nm. A possible advantage of the 1940 nm wavelength in terms of postoperative pain intensity and the risk of adverse events cannot be ruled out.
Eligibility Criteria
Inclusion Criteria: * Age \>18 years * Primary VVs of Clinical Etiology Anatomy Pathophysiology (CEAP) clinical class of C2-C6 * Reflux along the GSV trunk lasting \>0.5 sec. * GSV trunk diameter ≤12 mm * Informed consent to participate in the study Exclusion Criteria: * Primary reflux outside the GSV trunk (including combined reflux) * History of deep or superficial vein thrombosis * Deep vein reflux * Non-thrombotic or post-thrombotic venous obstruction * Pelvic venous insufficiency * Use of oral anticoagulants * Indication for pharmacological prophylaxis after EVLT * Inability to use radial fiber of 1.4-1.57 mm at the surgeon's discretion * Refusal to participate in the study
Contact & Investigator
Kirill Lobastov, PhD
PRINCIPAL INVESTIGATOR
Pirogov Russian National Research Medical University
Frequently Asked Questions
Who can join the NCT07449728 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Varicose Veins. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07449728 currently recruiting?
Yes, NCT07449728 is actively recruiting participants. Contact the research team at lobastov_kv@hotmail.com for enrollment information.
Where is the NCT07449728 trial being conducted?
This trial is being conducted at Moscow, Russia.
Who is sponsoring the NCT07449728 clinical trial?
NCT07449728 is sponsored by Pirogov Russian National Research Medical University. The principal investigator is Kirill Lobastov, PhD at Pirogov Russian National Research Medical University. The trial plans to enroll 400 participants.